1312547-99-1

Basic information

• Product Name: (S)-2-{5-[4-(6-bromothieno[3,2-b]thiophen-3-yl)phenyl]-1H-imidazol-2-yl}pyrrolidine-1-carboxylic acid tert-butyl ester
• Synonyms: (S)-2-{5-[4-(6-bromothieno[3,2-b]thiophen-3-yl)phenyl]-1H-imidazol-2-yl}pyrrolidine-1-carboxylic acid tert-butyl ester
• CAS NO: 1312547-99-1
• Molecular Weight: 530.509
• Mol File: 1312547-99-1.mol

Chemical Properties

• CAS DataBase Reference: (S)-2-{5-[4-(6-bromothieno[3,2-b]thiophen-3-yl)phenyl]-1H-imidazol-2-yl}pyrrolidine-1-carboxylic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-2-{5-[4-(6-bromothieno[3,2-b]thiophen-3-yl)phenyl]-1H-imidazol-2-yl}pyrrolidine-1-carboxylic acid tert-butyl ester(1312547-99-1)
• EPA Substance Registry System: (S)-2-{5-[4-(6-bromothieno[3,2-b]thiophen-3-yl)phenyl]-1H-imidazol-2-yl}pyrrolidine-1-carboxylic acid tert-butyl ester(1312547-99-1)

Safety Data

• Hazardous Substances Data: 1312547-99-1(Hazardous Substances Data)

Upstream product

• 392662-65-6 3,6-dibromothiophene[3,2-b]thiophene 
• 1007882-04-3 (S)-tert-butyl 2-(5-(4-bromophenyl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate 
• 1007881-98-2 y 
• 15761-39-4 1-(tert-butoxycarbonyl)-L-proline 

Relevant articles and documents

5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITORS

Provided herein are 5,5-fused heteroarylene hepatitis C virus inhibitor compounds, for example, of Formula I, IA, or IB, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.

METHODS FOR TREATING DRUG-RESISTANT HEPATITIS C VIRUS INFECTION WITH A 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITOR

Provided herein are methods for treating or preventing drug-resistant hepatitis C virus infection in a subject, which comprises administering to the subject a 5,5-fused heteroarylene hepatitis C virus inhibitor compound, for example, of Formula I, IA, or IB.

5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITORS

Provided herein are 5,5-fused heteroarylene hepatitis C virus inhibitor compounds, for example, of Formula I, IA, or IB, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.